Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 5/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779560 | 0.87 | KMT2A (0.51) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL13857882 | 0.83 | ALDH1A1 (0.55) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL7834836 | 0.83 | SLC6A9 (0.47) | SLC6A9ALDH1A1KMT2AOPRD1 | |
| SCHEMBL16759363 | 0.82 | SLC6A9 (0.46) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL21641193 | 0.81 | CACNA2D1 (0.50) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL21640152 | 0.81 | OPRD1 (0.49) | SLC6A9ALDH1A1KMT2AOPRD1 | |
| SCHEMBL72670 | 0.80 | MEN1 (0.48) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL17726230 | 0.79 | KMT2A (0.45) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL85389 | 0.79 | SLC6A9 (0.42) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL1221931 | 0.79 | SLC6A9 (0.46) | SLC6A9CACNA2D1CACNB1CACNA1CCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | SLC6A9 1870/4885CACNA2D1 306/4885CACNB1 312/4885 |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | SLC6A9 2277/4885CACNA2D1 3906/4885CACNB1 3893/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | SLC6A9 2300/4885CACNA2D1 3902/4885CACNB1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.